PrObe-L: Safety Study of Lenalidomide/Dexamethasone to Treat Patients With Relapsed or Refractory Multiple Myeloma

Sponsor

Celgene (Industry)

Overall Status

Completed

CT.gov ID

NCT02692339

Collaborator

(none)

Enrollment

Locations

33.5

Actual Duration (Months)

1.8

Patients Per Site

0.1

Patients Per Site Per Month

Study Details

Study Description

Brief Summary

Multicentre, prospective, observational, open-label, single arm, post-marketing study intended to record Lenalidomide/Dexamethasone treatment data from patients with relapsed/refractory Multiple Myeloma (rrMM) treated under the settings defined by the standard clinical practice and approved Summary of Product Characteristics (SmPC).

Condition or Disease	Intervention/Treatment	Phase
Multiple Myeloma	Drug: Lenalidomide Drug: Dexamethasone

Detailed Description

This study aims to assess the real-life safety of Lenalidomide/Dexamethasone (Len/Dex) in patients with (Relapsed or Refractory Multiple Myeloma (rrMM), by evaluation of adverse events of special interest (infections, gastrointestinal events, thrombocytopenia, neutropenia, febrile neutropenia, and thromboembolism). In addition, due to the scarce information regarding the impact of frailty in Len/Dex treatment in rrMM, this study will prospectively assess Len/Dex safety and effectiveness by patient frailty groups.

The following study assessments will be performed:

Recruitment: patients will be recruited within 15 days after the start of Len/Dex (from day 1 to day 15). In case patients are not recruited at the day of Len/Dex start (day 1), baseline information respective to this day will be collected retrospectively.
Treatment period: during this period, the following assessments will be carried out:
Every 30 days (± 5 days) for adverse events, changes in concomitant medication and change in Len/Dex dose.
Every 90 days (± 15 days) for the remaining information to be collected in the treatment period
Assessment at the end of Len/Dex treatment (until 5 days after end of treatment).

Follow-up assessment 90 days (± 15 days) after the end of Len/Dex treatment.

No visits were predefined for this study. Study data is planned to be collected when the patient goes to the study site for a clinical routine visit. No assessments will be imposed for the purposes of this study. If the patient goes to the clinical routine visit at a date out of the time intervals predicted above, no information will be collected. Information will be collected in the context of routine clinical practice.

The patient will be followed until the end of Len/Dex treatment, death or discontinuation for any reason for a maximum period of 36 months, Patients within treatment after this maximum period will stop being followed in the study.

Study Design

Study Type:

Observational [Patient Registry]

Actual Enrollment :

22 participants

Observational Model:

Cohort

Time Perspective:

Prospective

Official Title:

Prospective Observational Study Evaluating the Safety of Lenalidomide/Dexamethasone Treatment in Patients With Relapsed or Refractory Multiple Myeloma

Actual Study Start Date :

Feb 25, 2016

Actual Primary Completion Date :

Dec 12, 2018

Actual Study Completion Date :

Dec 12, 2018

Arms and Interventions

Arm	Intervention/Treatment
Lenalidomide/Dexamethasone Standard of Care doses for relapsed/refractory multiple myeloma	Drug: Lenalidomide Standard of Care doses for relapsed/refractory multiple myeloma: 25 mg/day lenalidomide 21 of 28 days cycle Other Names: Revlimid Drug: Dexamethasone Standard of Care doses for relapsed/refractory multiple myeloma: dexamethasone 40 mg/day at day 1,8,15,22 at 28 days cycle Other Names: Decadron

Arm

Intervention/Treatment

Lenalidomide/Dexamethasone

Standard of Care doses for relapsed/refractory multiple myeloma

Drug: Lenalidomide

Standard of Care doses for relapsed/refractory multiple myeloma: 25 mg/day lenalidomide 21 of 28 days cycle

Other Names:

Revlimid

Drug: Dexamethasone

Standard of Care doses for relapsed/refractory multiple myeloma: dexamethasone 40 mg/day at day 1,8,15,22 at 28 days cycle

Other Names:

Decadron

Outcome Measures

Primary Outcome Measures

Number of Adverse events of special interest during Len/Dex therapy [Up to approximately 72 months]
Adverse event (AE): Any untoward medical occurrence in a patient administered a pharmaceutical product and which does not necessarily have a causal relationship with this treatment, i.e. any unfavourable and unintended sign, symptom, or disease temporally associated with the use of a medicinal product whether or not considered related to the medicinal product. Progression of the underlying disease of multiple myeloma is not considered an AE and should not be reported as an AE

Secondary Outcome Measures

Incidence (number) of thromboembolism [Up to approximately 72 months]
Identification of the incidence of deep venous thrombosis and pulmonary embolism) during Lenalidomide and Dexamethasone study drug treatment.
Duration of Len/Dex treatment over the course of the study [Up to approximately 72 months]
Defined as the time between the start of Len/Dex treatment until discontinuation or death (whichever occurs first)
Number of patients with good and poor compliance to lenalidomide and dexamethasone [Up to approximately 72 months]
Compliance will be measured by the capsule/tablet count, after the end of study treatment
Type and frequency of prophylaxis treatment for prevention of thromboembolism [Up to 36 months]
Type and frequency of prophylaxis treatment for prevention of thromboembolism during Lenalidomide/Dexamethasone study treatment.

Eligibility Criteria

Criteria

Ages Eligible for Study:

18 Years and Older

Sexes Eligible for Study:

All

Accepts Healthy Volunteers:

Inclusion Criteria:

Patients aged 18 years or higher.
Patients who have voluntarily given written informed consent to participate in the study and have their data retrieved for the purposes of the study
Patients diagnosed with 1st or 2nd relapsed or refractory multiple myeloma and indicated for 2nd or 3rd line Len/Dex treatment, according with the SmPC (patients who have received at least one prior therapy) -

Exclusion Criteria:

Pregnant or lactating patients
Female patients of childbearing potential unable or unwilling to use effective contraceptive methods, as stated in the summary of product characteristics:

Implant.
Levonorgestrel-releasing intrauterine system.
Medroxyprogesterone acetate depot.
Tubal sterilisation.
Sexual intercourse with a vasectomised male partner only; vasectomy must be confirmed by two negative semen analyses.

Ovulation inhibitory progesterone-only pills (i.e. desogestrel).

Male patients unable to follow or comply with the required contraceptive measures stated in the SmPC (use of condom if engaged in sexual activity with a pregnant woman or a woman of childbearing potential not using effective contraception [even if the man has had a vasectomy], during treatment and for 1 week after dose interruptions and/or cessation of treatment)

Hypersensitivity to the active substance or any of the excipients
Patients participating in a clinical trial -

Contacts and Locations

Locations

	Site	City	Country	Postal Code
1	Hospital Garcia Orta, E.P.E.	Almada	Portugal	2805-267 Almada
2	Hospital Professor Doutor Fernando Fonseca, E.P.E.	Amadora	Portugal	2720-276 Amadora
3	Hospital Central de Faro	Faro	Portugal	8000-386 Faro
4	Instituto Português de Oncologia de Lisboa Francisco Gentil, EPE	Lisboa	Portugal	1099-023 Lisboa
5	Centro Hospitalar Lisboa Central, EPE - Hospital de Sto. Ant. Capuchos	Lisboa	Portugal	1169-050 Lisboa
6	Fundação Champalimaud	Lisboa	Portugal	1400-038 Lisboa
7	Centro Hospitalar Lisboa Norte, EPE - Hospital Santa Maria	Lisboa	Portugal	1649-035 Lisboa
8	Centro Hospitalar do Porto - Hospital de Santo António	Porto	Portugal	4099-001 Porto
9	Instituto Português de Oncologia do Porto Francisco Gentil, EPE	Porto	Portugal	4200-072 Porto
10	Centro Hospitalar de São João, EPE - Hospital de São João	Porto	Portugal	4200-319 Porto
11	Centro Hospitalar de Vila Nova de Gaia	Vila Nova de Gaia	Portugal	4430-502 Vila Nova de Gaia
12	Hospital de São Teotónio, E.P.E.	Viseu	Portugal	3504-509 Viseu